9 completed, 2 withdrawn, 1 no longer available. 6 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Withdrawn 2 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow DOXO-EMCH: new trials by email Literature Review of DOXO-EMCH trials Research Report on DOXO-EMCH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Nab-paclitaxel, Cisplatin, 5Fluorouracil - Non Small Cell Lung Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-06-01 | 2025-02-21 | |
| Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Aldoxorubicin, Topotecan - Metastatic Small Cell Lung Cancer | Phase 2 | Completed | ImmunityBio, Inc. | 135 | 2015-04-20 | 2024-06-25 |
| Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors aldoxorubicin, gemcitabine - Metastatic Solid Tumors | Phase 1 | Completed | ImmunityBio, Inc. | 30 | 2014-08-01 | 2022-02-10 |
| Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin - Glioblastoma | Phase 2 | Completed | ImmunityBio, Inc. | 28 | 2014-03-01 | 2024-05-29 |
| Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) - Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | Phase 3 | Completed | ImmunityBio, Inc. | 433 | 2014-01-01 | 2024-06-13 |
| Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors aldoxorubicin - Advanced Solid Tumors | Phase 1 | Completed | ImmunityBio, Inc. | 18 | 2012-10-01 | 2022-02-10 |
| Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors aldoxorubicin - Advanced Solid Tumor | Phase 1 | Completed | ImmunityBio, Inc. | 15 | 2012-07-01 | 2022-02-10 |
| Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer INNO-206 - Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | ImmunityBio, Inc. | 15 | 2012-05-16 | 2024-06-06 |
| Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma INNO-206, Doxorubicin - Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma | Phase 2 | Completed | ImmunityBio, Inc. | 126 | 2012-01-11 | 2024-05-29 |
| Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors INNO-206 - Malignant Solid Tumour | Phase 1 | Completed | ImmunityBio, Inc. | 24 | 2011-04-01 | 2022-02-10 |
| INNO-206 in Patients With Small Cell Lung Cancer (SCLC) INNO-206 - Small Cell Lung Cancer | Phase 2 | Withdrawn | CytRx | 2008-05-01 | 2012-02-09 | |
| Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy aldoxorubicin - Sarcoma | No longer available | CytRx | 2015-10-22 |
Sarcoma (3) · Neoplasm Metastasis (2) · Small Cell Lung Carcinoma (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Pancreatic Neoplasms (1)
ImmunityBio, Inc. (10) · CytRx (2)
United States (12) · Hungary (3) · Australia (2) · Russia (2) · Spain (2) · Canada (1) · Chile (1) · Denmark (1) · France (1) · India (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Romania (1)
Dan Levitt, MD (2) · Sant Chawla, M.D. (2) · Dan Levitt, M.D. (1) · Daniel Levitt, M.D., Ph.D. (1) · Daniel Levitt, MD, PhD (1) · Daniel Von Hoff, MD, FACP (1) · Michael Maitland, MD (1)